Evidence map›Paper›PMID 40025093›Full record

ArticleNature communications2025

A nanovaccine for immune activation and prophylactic protection of atherosclerosis in mouse models.

Lei Zhang, Abdulrahman Al-Ammari, Danxuan Zhu, Hongsong Zhang, Peng Zhou, Xu Zhi, Weixiao Ding, Xinmeng Li, Qingqing Yu, Yuwen Gai and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  3. CIITA/PRMT5 promote CD4BMC medicine · 2026
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lei Zhang *Chemicobiology and Functional Materials Institute, School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing, PR China.ORCID http://orcid.org/0000-0002-9312-8278
Abdulrahman Al-Ammari *School of Chemistry and Materials Science, University of Science and Technology of China, Hefei, PR China.
Danxuan ZhuThe First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
Hongsong ZhangDepartment of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, PR China.ORCID http://orcid.org/0000-0003-4251-7609
Peng ZhouChemicobiology and Functional Materials Institute, School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing, PR China.
Xu ZhiState Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, PR China.
Weixiao DingChemicobiology and Functional Materials Institute, School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing, PR China.
Xinmeng LiChemicobiology and Functional Materials Institute, School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing, PR China.
Qingqing YuChemicobiology and Functional Materials Institute, School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing, PR China.
Yuwen GaiChemicobiology and Functional Materials Institute, School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing, PR China.
Xiaoling MaThe First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
Chuntao ChenChemicobiology and Functional Materials Institute, School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing, PR China.
Chao ZuoSchool of Electronic and Optical Engineering, Nanjing University of Science and Technology, Nanjing, PR China.ORCID http://orcid.org/0000-0002-1461-0032
Jiaan ZhangInstitute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, PR China. jazhang618@126.com.
Wanying ZhuSchool of Pharmacy, Nanjing Medical University, Nanjing, PR China. wanyingzhu@njmu.edu.cn.ORCID http://orcid.org/0000-0002-6292-4108
Dongping SunChemicobiology and Functional Materials Institute, School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing, PR China. sundpe301@163.com.ORCID http://orcid.org/0000-0001-5555-1588

Funding

National Natural Science Foundation of China (National Science Foundation of China) 21904069National Natural Science Foundation of China (National Science Foundation of China) 22274079National Natural Science Foundation of China (National Science Foundation of China) 51803092National Natural Science Foundation of China (National Science Foundation of China) 51873087National Natural Science Foundation of China (National Science Foundation of China) 81801839National Natural Science Foundation of China (National Science Foundation of China) 82200497Natural Science Foundation of Jiangsu Province (Jiangsu Provincial Natural Science Foundation) BK20190653Natural Science Foundation of Jiangsu Province (Jiangsu Provincial Natural Science Foundation) BK20240131
6 · The paper itself

Abstract

Vaccines offer prophylactic treatments against atherosclerosis by eliciting effector T cell and antibody responses, which require effective delivery of antigen and adjuvant to activate dendritic cells (DC). Here we show that individual conjugation of antigen p210 and adjuvant CpG oligodeoxynucleotides onto superparamagnetic iron oxide nanoparticles formulates a nanovaccine cocktail that activates DCs for antigen cross-presentation and induction of co-stimulatory signals, cytokines and CD8

Indexed as

AtherosclerosisVaccinesAdjuvants, ImmunologicAnimalsApolipoproteins ECD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDendritic CellsDisease Models, AnimalFemaleMaleMiceMice, Inbred C57BLMice, KnockoutMice, Knockout, ApoENanoparticlesAdjuvants, ImmunologicApolipoproteins ECPG-oligonucleotideNanovaccinesOligodeoxyribonucleotidesVaccines

Identifiers

PMID40025093
PMCPMC11873251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.